ALNY – Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.ALNY
$266.86Name : Alnylam Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $34,795,339,776.00
EPSttm : -2.11
Alnylam Pharmaceuticals, Inc.
$266.86
1.23%$3.33Float Short %
2.53
Margin Of Safety %
Put/Call OI Ratio
0.69
EPS Next Q Diff
0.9
EPS Last/This Y
3.24
EPS This/Next Y
2.89
Price
266.86
Target Price
324.46
Analyst Recom
1.74
Performance Q
-0.79
Relative Volume
0.72
Beta
0.17
Ticker: ALNY
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | ALNY | 239.94 | 0.69 | 0.47 | 25977 |
| 2025-04-15 | ALNY | 230.6 | 0.69 | 3.09 | 26946 |
| 2025-04-16 | ALNY | 230.48 | 0.65 | 1.47 | 26392 |
| 2025-04-17 | ALNY | 234.47 | 0.64 | 0.16 | 26316 |
| 2025-04-18 | ALNY | 234.56 | 0.64 | 0.19 | 26316 |
| 2025-04-21 | ALNY | 232.65 | 0.76 | 0.24 | 15528 |
| 2025-04-22 | ALNY | 236.79 | 0.76 | 0.31 | 15534 |
| 2025-04-23 | ALNY | 241.66 | 0.77 | 0.08 | 15653 |
| 2025-04-24 | ALNY | 242.44 | 0.76 | 0.64 | 15838 |
| 2025-04-25 | ALNY | 251.56 | 0.75513585155732 | 1.0119331742243 | 15891 |
| 2025-04-28 | ALNY | 254.85 | 0.72886576040782 | 1.2 | 16279 |
| 2025-04-29 | ALNY | 256.19 | 0.73 | 0.05 | 16321 |
| 2025-04-30 | ALNY | 263.03 | 0.74 | 0.43 | 16244 |
| 2025-05-01 | ALNY | 255.35 | 0.73 | 1.79 | 16341 |
| 2025-05-02 | ALNY | 259.33 | 0.76 | 0.24 | 16469 |
| 2025-05-05 | ALNY | 273.71 | 0.76 | 0.24 | 16474 |
| 2025-05-06 | ALNY | 269.91 | 0.75 | 0.07 | 16659 |
| 2025-05-07 | ALNY | 276.6 | 0.71 | 0.82 | 17212 |
| 2025-05-08 | ALNY | 258.35 | 0.72 | 0.87 | 17223 |
| 2025-05-09 | ALNY | 251.26 | 0.71 | 0.38 | 17689 |
| 2025-05-12 | ALNY | 270.18 | 0.68 | 0.32 | 18088 |
| 2025-05-13 | ALNY | 267.86 | 0.69 | 0.51 | 18026 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | ALNY | 240.01 | -124.1 | 194.5 | 0.83 |
| 2025-04-15 | ALNY | 230.93 | -115.3 | 196.5 | 0.81 |
| 2025-04-16 | ALNY | 230.49 | -115.3 | 194.9 | 0.81 |
| 2025-04-17 | ALNY | 234.56 | -115.3 | 194.1 | 0.81 |
| 2025-04-18 | ALNY | 234.56 | -115.3 | 194.9 | 0.81 |
| 2025-04-21 | ALNY | 232.75 | -115.3 | 195.2 | 0.81 |
| 2025-04-22 | ALNY | 236.75 | -82.0 | 265.2 | 0.78 |
| 2025-04-23 | ALNY | 241.97 | -130.9 | 265.4 | 0.72 |
| 2025-04-24 | ALNY | 242.59 | -130.9 | 264.8 | 0.72 |
| 2025-04-25 | ALNY | 251.56 | -130.9 | 265.8 | 0.72 |
| 2025-04-28 | ALNY | 254.85 | -130.9 | 265.1 | 0.72 |
| 2025-04-29 | ALNY | 257.19 | -130.9 | 265.0 | 0.72 |
| 2025-04-30 | ALNY | 263.31 | -130.9 | 265.4 | 0.72 |
| 2025-05-01 | ALNY | 255.18 | -130.9 | 263.8 | 0.72 |
| 2025-05-02 | ALNY | 259.39 | -130.9 | 265.1 | 0.72 |
| 2025-05-05 | ALNY | 273.68 | -108.7 | 241.0 | 0.84 |
| 2025-05-06 | ALNY | 270.14 | -126.8 | 240.1 | 1.07 |
| 2025-05-07 | ALNY | 276.55 | -126.8 | 272.4 | 1.07 |
| 2025-05-08 | ALNY | 258.34 | -121.1 | 266.6 | 1.06 |
| 2025-05-09 | ALNY | 251.21 | -121.1 | 269.0 | 1.06 |
| 2025-05-12 | ALNY | 270.19 | -121.1 | 275.6 | 1.06 |
| 2025-05-13 | ALNY | 266.86 | -121.1 | 270.0 | 1.06 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | ALNY | -2.05 | -0.09 | 2.40 |
| 2025-04-15 | ALNY | -2.05 | -0.09 | 2.40 |
| 2025-04-16 | ALNY | -2.05 | -0.09 | 2.40 |
| 2025-04-17 | ALNY | -2.05 | -0.09 | 2.40 |
| 2025-04-18 | ALNY | -2.05 | -0.09 | 2.40 |
| 2025-04-21 | ALNY | -2.05 | 0.06 | 2.40 |
| 2025-04-22 | ALNY | -2.05 | 0.06 | 2.40 |
| 2025-04-23 | ALNY | -2.05 | 0.06 | 2.40 |
| 2025-04-24 | ALNY | -2.05 | 0.06 | 2.40 |
| 2025-04-25 | ALNY | -2.05 | 0.06 | 2.40 |
| 2025-04-28 | ALNY | -2.05 | 0.07 | 2.46 |
| 2025-04-29 | ALNY | -2.05 | 0.07 | 2.46 |
| 2025-04-30 | ALNY | -2.05 | 0.07 | 2.46 |
| 2025-05-01 | ALNY | -2.05 | 0.07 | 2.46 |
| 2025-05-02 | ALNY | -2.05 | 0.07 | 2.46 |
| 2025-05-05 | ALNY | -2.05 | 0.28 | 2.46 |
| 2025-05-06 | ALNY | -2.05 | 0.28 | 2.46 |
| 2025-05-07 | ALNY | -2.05 | 0.28 | 2.46 |
| 2025-05-08 | ALNY | -2.05 | 0.28 | 2.46 |
| 2025-05-09 | ALNY | -2.05 | 0.28 | 2.46 |
| 2025-05-12 | ALNY | -2.06 | -0.25 | 2.53 |
| 2025-05-13 | ALNY | -2.06 | -0.25 | 2.53 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.44
Avg. EPS Est. Current Quarter
-0.12
Avg. EPS Est. Next Quarter
0.46
Insider Transactions
-2.06
Institutional Transactions
-0.25
Beta
0.17
Average Sales Estimate Current Quarter
623
Average Sales Estimate Next Quarter
723
Fair Value
Quality Score
45
Growth Score
55
Sentiment Score
71
Actual DrawDown %
12.3
Max Drawdown 5-Year %
-42.5
Target Price
324.46
P/E
Forward P/E
148.51
PEG
P/S
14.82
P/B
301.25
P/Free Cash Flow
EPS
-2.09
Average EPS Est. Cur. Y
1.06
EPS Next Y. (Est.)
3.96
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-11.49
Relative Volume
0.72
Return on Equity vs Sector %
-257.3
Return on Equity vs Industry %
-240.4
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
0.24
EBIT Estimation
270
Alnylam Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 2230
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
stock quote shares ALNY – Alnylam Pharmaceuticals, Inc. Stock Price stock today
news today ALNY – Alnylam Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALNY – Alnylam Pharmaceuticals, Inc. yahoo finance google finance
stock history ALNY – Alnylam Pharmaceuticals, Inc. invest stock market
stock prices ALNY premarket after hours
ticker ALNY fair value insiders trading